The aim of the study is to determine the efficacy and safety in treating patients with chronic central serous chorioretinopathy with the drug eplerenone.

• The goal of the study is to examine the short-term effects and safety of eplerenone, a systemic anti-aldosterone medication, in a group of patients with central serous chorioretinopathy (CSCR).
• There is currently no standard treatment or therapy for chronic CSCR, a potentially debilitating eye disease.
• There is evidence that high blood serum corticosteroid levels can cause or worsen CSCR
• Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR
• The study's aim is to evaluate a standardized dose of eplerenone in a controlled prospective fashion for chronic CSCR.
• The study consists of taking a standard dose of eplerenone, 25mg once daily for a week, followed by 50mg once daily, for a total of 3 months
• Patients will be monitored for efficacy and side effects from the beginning of treatment and for 6 months

Inclusion Criteria:

• Chronic central serous chorioretinopathy (CSCR): Previous diagnosis of CSCR, persistent subretinal fluid on OCT for more than 4 months after initial presentation to the eye clinic

Exclusion Criteria:

• Other retinal disease
• Choroidal neovascularization
• Diabetes
• A history of uveitis
• Ocular surgery in the prior 3 months
• Allergy to fluorescein or indocyanine green
• Pregnancy, lactation or female patients in fertility age not treated with contraceptive pills
• Creatinine clearance < 50 ml/min
• Hyperkalemia > 5 mmol/l
• Patients treated with drugs deactivated by cytochrome P450 3A4 (CYP3A4)
• Serum creatinine > 2 mg/dl in men or > 1.8 mg/dl in women
• Treatment with potassium sparing agents or potassium
• Treatment with Angiotensin converting enzyme (ACE)/angiotensin II receptor blocker (ARB) inhibitors